YGION Biomedical

YGION Biomedical GmbH develops individualized neoantigen-based cancer vaccines. Their YGNITE™ technology platform identifies, produces, and targets the delivery of relevant peptide neoepitopes to activate the patient's immune system. This results in safe, potent, and precise targeted cancer treatment.

Buy Funded Startups lists

Funding Round: Series A

Funding Amount: €15M

Date: 21-May-2024

Investors: An Austrian private trust

Markets: Biotechnology, Oncology, Immunotherapy

HQ: Vienna, Vienna, Austria

Founded: 2022

Website: http://www.ybion.bio/

LinkedIn: https://www.linkedin.com/company/ygion-biomedical/

Twitter:

Instagram: